Sucampo Pharmaceuticals, Inc. (SCMP) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.02, Bloomberg Earnings reports. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The firm had revenue of $61.27 million for the quarter, compared to the consensus estimate of $58.05 million. During the same period in the prior year, the business posted $0.30 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Sucampo Pharmaceuticals updated its FY17 guidance to $1.10-1.15 EPS.
Several equities research analysts have recently weighed in on SCMP shares. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. UBS AG reduced their price target on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a “buy” rating on the stock in a report on Thursday, October 12th. Mizuho downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $14.00 to $12.00 in a report on Tuesday, October 3rd. TheStreet downgraded Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a report on Wednesday, August 2nd. Finally, Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $16.50.
In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jones W. Bryan bought 4,700 shares of the business’s stock in a transaction on Friday, August 4th. The stock was purchased at an average cost of $10.60 per share, for a total transaction of $49,820.00. Following the transaction, the insider now owns 4,700 shares of the company’s stock, valued at $49,820. The disclosure for this purchase can be found here. 4.13% of the stock is owned by insiders.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.